These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18305058)

  • 41. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
    Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
    Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of mTOR inhibitors on the development of malignancy.
    Geissler EK
    Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antitumoral effect of proliferation signal inhibitors].
    Dumortier J
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.
    Elit L
    IDrugs; 2006 Sep; 9(9):636-44. PubMed ID: 16952072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
    Sonis S; Treister N; Chawla S; Demetri G; Haluska F
    Cancer; 2010 Jan; 116(1):210-5. PubMed ID: 19862817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies.
    Altman JK; Platanias LC
    Curr Opin Hematol; 2008 Mar; 15(2):88-94. PubMed ID: 18300753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the mTOR pathway using deforolimus in cancer therapy.
    Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
    Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
    Pantuck AJ; Thomas G; Belldegrun AS; Figlin RA
    Semin Oncol; 2006 Oct; 33(5):607-13. PubMed ID: 17045090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
    Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting mTOR in renal cell carcinoma.
    Hudes GR
    Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
    Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
    J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
    Dancey JE; Curiel R; Purvis J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Defining the role of mTOR in cancer.
    Guertin DA; Sabatini DM
    Cancer Cell; 2007 Jul; 12(1):9-22. PubMed ID: 17613433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NCCN Task Force Report: mTOR inhibition in solid tumors.
    Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
    J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Mammalian target of rapamycin inhibitors for the targeted therapy of non-small cell lung cancer].
    Lin Y; Zhang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr; 32(2):239-42. PubMed ID: 20450558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention.
    Kopelovich L; Fay JR; Sigman CC; Crowell JA
    Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1330-40. PubMed ID: 17626998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapamycin: something old, something new, sometimes borrowed and now renewed.
    Hartford CM; Ratain MJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):381-8. PubMed ID: 17728765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.